BIOMAT Database Logo BIOMAT Database Logo

Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors. 2020

Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, 200433, People's Republic of China; Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai, 200433, People's Republic of China.

The fragment hopping approach is widely applied in drug development. A series of diarylpyrimidines (DAPYs) were obtained by hopping the thioacetamide scaffold to novel human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitors (NNRTIs) to address the cytotoxicity issue of Etravirine and Rilpivirine. Although the new compounds (11a-l) in the first-round optimization possessed less potent anti-viral activity, they showed much lower cytotoxicity. Further optimization on the sulfur led to the sulfinylacetamide-DAPYs exhibiting improved anti-viral activity and a higher selectivity index especially toward the K103N mutant strain. The most potent compound 12a displayed EC50 values of 0.0249 μM against WT and 0.0104 μM against the K103N mutant strain, low cytotoxicity (CC50 > 221 μM) and a high selectivity index (SI WT > 8873, SI K103N > 21186). In addition, this compound showed a favorable in vitro microsomal stability across species. Computational study predicted the binding models of these potent compounds with HIV-1 reverse transcriptase thus providing further insights for new developments.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
[Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
February 2010, Yao xue xue bao = Acta pharmaceutica Sinica,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
October 2018, European journal of medicinal chemistry,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.
January 2016, Current topics in medicinal chemistry,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs.
March 2020, Molecules (Basel, Switzerland),
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly.
January 2006, Current pharmaceutical design,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
April 2023, Communications chemistry,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
June 2009, Journal of medicinal chemistry,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
June 2010, ChemMedChem,
Sheng Han, and Yali Sang, and Yan Wu, and Yuan Tao, and Christophe Pannecouque, and Erik De Clercq, and Chunlin Zhuang, and Fen-Er Chen
Novel diarylpyrimidine subtypes as HIV-1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile.
March 2024, Journal of medical virology,
Copied contents to your clipboard!